Scynexis (SCYX) Change in Accured Expenses (2013 - 2026)
Scynexis (SCYX) posted Change in Accured Expenses of -$1.4 million for Q1 2026, down 100.57% on a QoQ basis from -$704000.0 in Q4 2025, and down 21.41% year-over-year from -$1.8 million in Q1 2025.
Scynexis (SCYX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Scynexis' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 21.41% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (up 73.86% YoY) and the FY2025 annual result came in at -$1.0 million, up 72.93% from the prior year.
- Change in Accured Expenses was -$1.4 million for Q1 2026 at Scynexis, down from -$704000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $7.8 million in Q4 2023 and bottomed at -$5.8 million in Q1 2023.
- A 5-year average of -$254058.8 and a median of -$87000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 4991.84% — and 2025, when it jumped 1282.93%.
- Scynexis' Change in Accured Expenses stood at -$2.5 million in 2022, then soared by 414.31% to $7.8 million in 2023, then sank by 144.03% to -$3.5 million in 2024, then jumped by 79.61% to -$704000.0 in 2025, then sank by 100.57% to -$1.4 million in 2026.
- Business Quant data shows SCYX's Change in Accured Expenses at -$1.4 million in Q1 2026, -$704000.0 in Q4 2025, and -$105000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.19 Bn | 87.33 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.03 Bn | 32.29 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.72 Bn | 12.29 Bn | 785.00 Mn | - |
| 10 | Scynexis | 24.05 Mn | -12.71 Mn | - | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | -704,000.00 |
| Dec 31, 2025 | -704,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Mar 31, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -87,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -82,000.00 |
| Jun 30, 2024 | -82,000.00 |
| Mar 31, 2024 | -79,000.00 |
| Mar 31, 2024 | -79,000.00 |
| Dec 31, 2023 | 7.84 Mn |
| Dec 31, 2023 | 7.84 Mn |